In another placebo‐controlled, cross‐over trial in statin treated obese patients with T2DM and coronary artery disease, no change of CRP level was observed, but TNFα decreased in metformin alone group, implying that anti‐inflammatory activity of metformin was more related to the regulation of TNFα but not CRP in T2DM patients, consistent with previous trial. The gene discussed is CRP; the disease is coronary artery disorder.